Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband’s sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; obstetrics, gynecology, urology, internal medicine, and pediatrics medical services; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and engages in the investment management and management consultancy, postpartum and rehabilitation care, property investment, and real estate development and operation activities. Additionally, the company is involved in the sale of medicines, consumables, and equipment; and research and development of IVF related projects, including scientific research and related commercialization. Jinxin Fertility Group Limited was founded in 1951 and is headquartered in Chengdu, China.